ANTIBODIES
Contributor Information
- Name Ayham Alnabulsi
- Institute Vertebrate Antibodies Limited
Tool Details
- Tool name: Anti-sCTLA4 [L4P2F5*F10]
- Alternate names: Cytotoxic T-Lymphocyte Associated Protein 4; Insulin-Dependent Diabetes Mellitus 12; Celiac Disease 3; CTLA-4; CD152; CD152 Antigen; CELIAC3; IDDM12; ALPS5; GRD4; GSE; CD
- Clone: L4P2F5*F10
- Tool type: Antibodies
- Tool sub-type: Primary Antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Bovine ; Human ; Mouse ; Rat
- Host: Mouse
- Molecular weight of the target: 35 kDa
- Application: ELISA ; IHC ; WB
- Description: CTLA4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152, is a protein that plays an important regulatory role in the immune system. CTLA4 is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. Mutations in the CTLA4 gene have been associated with various autoimmune diseases, such as systemic lupus erythematosus, insulin-dependent diabetes mellitus, and other autoimmune diseases. A recently identified novel transcript of the CTLA-4 gene that may represent a native soluble form of CTLA-4 (sCTLA-4) showed that eleven of twenty patients with autoimmune thyroid disease (ATD ) had a high concentration of sCTLA-4, whereas only 1 of 30 apparently healthy volunteers contained measurable levels. sCTLA-4 immunoreactivity was inhibited by its binding to B7.1, suggesting that sCTLA-4 is a functional receptor. sCTLA4 also plays a role in the initial immune response to infection of immune cells by HIV, along with the CD-1 pathway and others. There is strong evidence showing variation of sCTLA4 levels between individuals ranging from approximately 150 to around 10,000 pg/ ml. One can speculate that those patients with high sCTLA4 levels are unlikely to benefit from CTLA4 therapy. Hence, it is crucial to measure/ quantify sCTLA4 before administering treatment. This anti-sCTLA4 antibody could prove a useful predictive biomarker.
- Immunogen: Ovalbumin-conjugated synthetic peptide CENAPNRARM
- Isotype: IgG1 kappa
- Research area: Immunology; Stem cell biology
- For Research Use Only
Target Details
- Target: Cytotoxic T-lymphocyte-associated protein 4, sCTLA4 molecule (sCTLA4 soluble form)
- Target molecular weight: 35 kDa
- Target background: CTLA4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152, is a protein that plays an important regulatory role in the immune system. CTLA4 is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. Mutations in the CTLA4 gene have been associated with various autoimmune diseases, such as systemic lupus erythematosus, insulin-dependent diabetes mellitus, and other autoimmune diseases. A recently identified novel transcript of the CTLA-4 gene that may represent a native soluble form of CTLA-4 (sCTLA-4) showed that eleven of twenty patients with autoimmune thyroid disease (ATD ) had a high concentration of sCTLA-4, whereas only 1 of 30 apparently healthy volunteers contained measurable levels. sCTLA-4 immunoreactivity was inhibited by its binding to B7.1, suggesting that sCTLA-4 is a Fn receptor. sCTLA4 also plays a role in the initial immune response to infection of immune cells by HIV, along with the CD-1 pathway and others. There is strong evidence showing variation of sCTLA4 levels between individuals ranging from approximately 150 to around 10,000 pg/ ml. One can speculate that those patients with high sCTLA4 levels are unlikely to benefit from CTLA4 therapy. Hence, it is crucial to measure/ quantify sCTLA4 before administering treatment. This anti-sCTLA4 antibody could prove a useful predictive biomarker.
Application Details
- Application: ELISA ; IHC ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15Ă°C to -25Ă°C
- Shipping conditions: Shipping at 4Ă°C
Documentation
.svg)
Unit size: 
.svg)
.svg)
